23 results about "Pyrophosphatase" patented technology

The invention belongs to the technical field of microbial pharmacy, and discloses a polyketone macrolide compound generated by genetically engineered streptomyces as well as a preparation method and application thereof. The polyketone macrolide compound disclosed by the invention is a cinnamyl streptomycin derivative, has cell proliferation inhibition activity better than that of a natural product Cinnamomycin A-D, can exert anti-tumor activity by inhibiting activity of human exonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1) and activating an inherent immune pathway, can be prepared into a medicine or a medicinal composition, and can be used for preparing medicines or medicinal compositions. The compound is used for treating tumors and related diseases.

The present disclosure relates generally to processes for providing compounds that can be used as inhibitors of ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1), which inhibitors can be useful in treating or preventing soft bone diseases, such as hypophosphatasia (HPP).

This specification describes methods for treating cancer using small molecule ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1) inhibitors and additional agents.

This invention generally relates to veterinary use of an ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1) inhibitor, e.g., for modulating (e.g., inhibiting) ENPP1 activity and / or signaling, for example, for the treatment or prophylaxis of periodontal disease or bone disorder, such as periodontitis.

The invention discloses a preparation method of all-trans-farnesol through a three-enzyme cascade reaction. The invention firstly provides a mutant of farnesyl pyrophosphate synthase, and the amino acid sequence of the mutant is shown as SEQ ID No.3. Compared with a wild type, the mutant is applied to enzyme catalytic synthesis of farnesol, so that the conversion rate of a gold product is remarkably improved. The invention also provides a three-enzyme cascade reaction preparation method of farnesol, which comprises the following steps: in the same reaction system, dimethyl allyl diphosphate is used as a substrate; according to the method, isopentenyl diphosphate isomerase, farnesyl pyrophosphate synthase or a mutant thereof and farnesyl pyrophosphatase are used as catalytic enzymes for enzymatic reaction to prepare all-trans-farnesyl alcohol. According to the invention, in a single reaction system, three key enzymes are combined for application, so that continuous catalysis, high-efficiency and high-selectivity preparation of all-trans-farnesol is realized, process steps are simplified, and a new way is provided for green and efficient preparation of farnesol.

The invention belongs to the technical field of molecular biology, and particularly discloses a method for improving citrus canker resistance by using a CsENPP1 gene, the coding protein of the CsENPP1 gene is citrus nucleotide pyrophosphatase / phosphodiesterase 1, the coding sequence of the CsENPP1 is a nucleotide sequence shown as SEQ ID No.1, and the citrus canker resistance is improved based on overexpression of the CsENPP1 gene in citrus cells. The citrus nucleotide pyrophosphatase / phosphodiesterase 1 coding gene is integrated into citrus through an expression vector, the canker attack degree of the obtained transgenic material can be reduced to 48.9% of that of the existing citrus to the maximum extent, the canker attack degree can be remarkably reduced, the scab area is reduced, and the yield of the citrus is improved. The technology provided by the invention is a bioengineering technology which has potential to improve the citrus canker resistance, and has great value for citrus canker resistance molecular breeding.

The present invention provides combinations of inhibitors of Ectonucleotide Pyrophosphatase / Phosphodiesterase (ENPP1) with a radiation therapy or a radioligand for the purposes of treating cancer. The invention includes both methods of treatment of cancer with the provided combinations and pharmaceutical compositions comprising such combinations. A preferred ENPP1 inhibitor is SR-8541A; and a preferred radioligand is PluvictoTM.

The present disclosure provides a therapeutic method of treating cancer metastasis by inducing clearance of EVs using a binding agent specific to an EV protein. The method utilizes one or more binding agents specific to EV proteins, where the EV proteins are selected from prostaglandin F2 receptor negative regulator (PTGFRN); basigin (BSG); immunoglobulin superfamily member 2 (IGSF2); immunoglobulin superfamily member 3 (IGSF3); immunoglobulin superfamily member 8 (IGSF8); integrin beta-1 (ITGB1); integrin alpha-4 (ITGA4); 4F2 cell-surface antigen heavy chain (SLC3A2); a class of ATP transporter proteins (ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B3, ATP2B1, ATP2B2, ATP2B3, ATP2B4); CD13 (aminopeptidase N); MME (neprilysin), ENPP1 (ectonucleotide pyrophosphatase / phosphodiesterase family member 1); and NRP1 (neuropilin-1). Further provided herein includes a pharmaceutical composition for the treatment of cancer metastasis.

The present invention relates to a pyrrolopyrimidinone derivative or pharmaceutically acceptable salt thereof, a composition for preventing or treating cancer comprising the derivative as an active ingredient, and the like, the pyrrolopyrimidinone derivative of the present invention being highly effective in inhibiting ENPP1 activity. Therefore, the present invention can be used for the purpose of treating, preventing, and alleviating cancerous diseases caused by abnormal cell growth. In addition, the pyrrolopyrimidinone derivative and pharmaceutically acceptable salt thereof of the present invention effectively inhibit ENPP1 to activate the STING pathway, and thus can be effectively used in preventing or treating cancer.

The present invention relates to a pharmaceutical composition for preventing, ameliorating, or treating calcium pyrophosphate deposition disease and hypophosphatasia, comprising a benzotriazole derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase.

The application relates to a rapamycin-G4H nanocapsule, a preparation method and application thereof. The preparation method of the rapamycin-G4H nanocapsule comprises the following steps: S1. preparing a rapamycin micelle by adopting a film hydration method; S2. modifying a dibenzocyclooctyne amplification primer on the surface of the rapamycin micelle through a click chemistry reaction to obtain a rapamycin micelle modified with the amplification primer; S3. taking a linear DNA molecule as a template, and synthesizing a circular amplification template through an intramolecular cyclization reaction; and S4. incubating the circular amplification template, the rapamycin micelle modified with the amplification primer, a thermophilic DNA polymerase, a pyrophosphatase, dNTP and Co-G4-haem DNAzyme under the condition of a thermophilic DNA polymerase reaction buffer. The rapamycin-G4H nanocapsule can play an efficient antioxidant stress and immune inflammatory regulation function, can improve the intraocular microenvironment of a glaucoma patient, and can inhibit the continuous apoptosis of retinal ganglion cells.

A method for treating hypophosphatasia (HPP) is provided herein, comprising administering a therapeutically effective dose of an ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1) inhibitor. A method for using an ENPP1 inhibitor to treat or prevent cartilage disease is disclosed herein. In some embodiments, the cartilage disease is hypophosphatasia. Ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1) is an extracellular enzyme that hydrolyzes ATP to PPi and AMP in the extracellular space.

The invention discloses a pyrophosphoric acid detection and regulation device and method for mRNA (messenger ribonucleic acid) in-vitro transcription. The device comprises an in-vitro transcription reaction module, a peristaltic pump sampling module, a pyrophosphoric acid fluorescence detection module, a photoelectric signal processing module, a control module and an actuating module. The pyrophosphoric acid fluorescence detection module is used for detecting reaction liquid containing pyrophosphoric acid, outputting a pyrophosphoric acid concentration signal and inputting the pyrophosphoric acid concentration signal to the photoelectric signal processing module for amplification treatment, and then the control module compares the collected pyrophosphoric acid concentration signal with a preset threshold value; when the pyrophosphoric acid concentration signal is larger than the preset threshold value, the actuating module is controlled to add pyrophosphatase into the in-vitro transcription reaction module so that the pyrophosphoric acid concentration can return to the preset threshold value range, real-time detection and regulation of the pyrophosphoric acid concentration are achieved, and the yield and quality of mRNA can be improved.

Disclosed is a method for constructing a synthesis and regeneration system based on APS as an active sulfonate donor, belonging to the technical field of biology. The present disclosure provides a new purpose of APS as an active sulfonate donor, and greatly improves the synthesis efficiency of the APS by screening different ATP sulfurylases and adding a pyrophosphatase into a reaction system to eliminate pyrophosphate as a byproduct. Further, the construction of a sulfonation modification system is realized by constructing an APS circulation regeneration system. Compared with a PAPS regeneration system, the APS circulation regeneration system has the advantages of short path and high efficiency, the sulfonation modification efficiency is significantly improved, and the synthesis cost is successfully reduced.

An objective of the present invention is to provide a novel benzotriazole derivative compound having ENPP1 inhibitory activity. [Solution] The present invention relates to novel benzotriazole derivative compounds, their tautomers, their pharma- ceutically acceptable salts, their hydrates or their stereoisomers, which are related to compounds for inhibiting ENPP1, compositions for inhibiting ENPP1 and methods for inhibiting ENPP1.

Provided are methods for treating cancer with an antibody that specifically binds to human Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and an ectonucleotide pyrophosphatase / phosphodiesterase family member 1 (ENPP1) inhibitor.

Solid state forms of small molecule exonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP1) inhibitors and pharmaceutical compositions comprising the solid state forms are described herein. The solid state forms and pharmaceutical compositions are useful for the treatment of diseases or disorders associated with ENPP1.

The application belongs to the technical field of molecular biology, and specifically discloses a method for improving the citrus canker resistance by using a CsENPP1 gene, wherein the coding protein of the CsENPP1 gene is a citrus nucleotide pyrophosphatase / phosphodiesterase 1, the CsENPP1 coding sequence is a nucleotide sequence shown in SEQ ID No. 1, and the citrus canker resistance is improved based on the overexpression of the CsENPP1 gene in citrus cells. The application integrates a citrus nucleotide pyrophosphatase / phosphodiesterase 1 coding gene into citrus through an expression vector, and the disease incidence of the obtained transgenic material can be reduced to 48.9% of that of the existing citrus at most, so that the disease incidence of the canker can be significantly reduced, and the lesion area can be reduced. The application is a biological engineering technology which has the potential to improve the citrus canker resistance, and has great value for the molecular breeding of the citrus canker resistance.

This invention generally relates to formulations comprising an ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1) inhibitor, kit comprising the same and methods of use comprising an ENPP1 inhibitor or a formulation comprising the same.

Provided are proteins capable of modifying 5' ends of RNA polynucleotides. The RNA polynucleotides are modified such that all or a portion of a 5' protecting group is removed by the protein. Methods of using the proteins to modify RNA polynucleotides, and kits containing the modified proteins are also provided.

Described herein are methods of treating cancer using small molecule exonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1) inhibitors and additional active agents.

The invention provides ultra-stable nano amorphous calcium phosphate and a preparation method thereof. A phosphate radical source of the amorphous calcium phosphate is adenosine triphosphate or pyrophosphate. The amorphous calcium phosphate contains alkaline phosphatase capable of hydrolyzing adenosine triphosphate, extracellular nucleotide pyrophosphatase 1 and alpha2-HS glycoprotein or secretory phosphoprotein 1 capable of stably adsorbing calcium ions. Researches prove that a mineralization raw material adenosine triphosphate involved in the mineralization process of a human body growth plate is used as a source of phosphate radicals, and protein capable of hydrolyzing adenosine triphosphate and pyrophosphate is sequentially added and combined with protein capable of adsorbing calcium ions, so that a spherical amorphous calcium phosphate cluster structure can be formed; and the formed amorphous calcium phosphate can stably exist for more than 35 days under the conditions that the pH is 7.0-7.3 and the temperature is 37 DEG C, and can stably exist for more than 120 days under the condition of 4 DEG C, so that the stabilization time of the nanoscale amorphous calcium phosphate under the mild condition is remarkably prolonged, and the method has a wide application prospect in the field of bone tissue engineering.